Using 3D imaging to assess pancreatic cancer prognosis
3D-MRE-Based Evaluation of Biomechanical Heterogeneity in Pancreatic Cancer and Its Clinical Prognosis
This study is testing if advanced 3D imaging can help doctors better understand the outlook for patients with pancreatic cancer by looking at the stiffness of the tissue around the tumor.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06849063 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) by utilizing advanced three-dimensional magnetic resonance elastography (3D-MRE). The study focuses on the biomechanical properties of the extracellular matrix surrounding PDAC, which are linked to tumor behavior and patient survival. By noninvasively measuring tissue stiffness, the research seeks to identify potential prognostic biomarkers that could guide treatment decisions and improve patient outcomes. The study will include patients with confirmed PDAC and will analyze their imaging data over a specified follow-up period.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with confirmed pancreatic ductal adenocarcinoma and no history of other malignancies.
Not a fit: Patients with very small tumors (less than 1.0 cm) or those who cannot undergo the imaging procedure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel noninvasive method for predicting survival in pancreatic cancer patients, leading to more personalized treatment strategies.
How similar studies have performed: While the use of MRE in other contexts has shown promise, this specific application for predicting PDAC prognosis is novel and has not been systematically explored in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. granting of written informed consent 2. age ≥18 years 3. no history of extrapancreatic malignancy 4. no preoperative biliary drainage 5. definitive histologic evidence of PDAC in excisional biopsy 6. with no less than three months of postoperative mortality or six months of follow- up Exclusion Criteria: 1. inability to re-review of tissue specimens 2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection 3. tumor diameters \<1.0 cm 4. withdrawal/dropout during follow-up
Where this trial is running
Shenyang, Liaoning
- Shengjing hospital of China medical university — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Yu Shi, MD.PhD. — Study Principal Investigator
- Study coordinator: Yu Shi, MD.PhD.
- Email: 18940259980@163.com
- Phone: 18940259980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.